Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

2.

Major milestones in translational oncology.

Dragani TA, Castells A, Kulasingam V, Diamandis EP, Earl H, Iams WT, Lovly CM, Sedelaar JP, Schalken JA.

BMC Med. 2016 Jul 28;14(1):110. doi: 10.1186/s12916-016-0654-y.

3.

Circulating Tumor DNA as a Cancer Biomarker: Fact or Fiction?

Leung F, Kulasingam V, Diamandis EP, Hoon DS, Kinzler K, Pantel K, Alix-Panabières C.

Clin Chem. 2016 Aug;62(8):1054-60. doi: 10.1373/clinchem.2016.260331. Epub 2016 Jun 3. No abstract available.

4.

Deciphering the peptidome of urine from ovarian cancer patients and healthy controls.

Smith CR, Batruch I, Bauça JM, Kosanam H, Ridley J, Bernardini MQ, Leung F, Diamandis EP, Kulasingam V.

Clin Proteomics. 2014 Jun 2;11(1):23. doi: 10.1186/1559-0275-11-23. eCollection 2014.

5.

Deciphering the ovarian cancer ascites fluid peptidome.

Bery A, Leung F, Smith CR, Diamandis EP, Kulasingam V.

Clin Proteomics. 2014 Apr 2;11(1):13. doi: 10.1186/1559-0275-11-13.

6.

Targeted selected reaction monitoring mass spectrometric immunoassay for insulin-like growth factor 1.

Niederkofler EE, Phillips DA, Krastins B, Kulasingam V, Kiernan UA, Tubbs KA, Peterman SM, Prakash A, Diamandis EP, Lopez MF, Nedelkov D.

PLoS One. 2013 Nov 21;8(11):e81125. doi: 10.1371/journal.pone.0081125. eCollection 2013.

7.

Folate-receptor 1 (FOLR1) protein is elevated in the serum of ovarian cancer patients.

Leung F, Dimitromanolakis A, Kobayashi H, Diamandis EP, Kulasingam V.

Clin Biochem. 2013 Oct;46(15):1462-8. doi: 10.1016/j.clinbiochem.2013.03.010. Epub 2013 Mar 23.

8.

Fascin-1 is a novel biomarker of aggressiveness in some carcinomas.

Kulasingam V, Diamandis EP.

BMC Med. 2013 Feb 26;11:53. doi: 10.1186/1741-7015-11-53.

9.

Rapid development of sensitive, high-throughput, quantitative and highly selective mass spectrometric targeted immunoassays for clinically important proteins in human plasma and serum.

Krastins B, Prakash A, Sarracino DA, Nedelkov D, Niederkofler EE, Kiernan UA, Nelson R, Vogelsang MS, Vadali G, Garces A, Sutton JN, Peterman S, Byram G, Darbouret B, Pérusse JR, Seidah NG, Coulombe B, Gobom J, Portelius E, Pannee J, Blennow K, Kulasingam V, Couchman L, Moniz C, Lopez MF.

Clin Biochem. 2013 Apr;46(6):399-410. doi: 10.1016/j.clinbiochem.2012.12.019. Epub 2013 Jan 8.

10.

CUB and zona pellucida-like domain-containing protein 1 (CUZD1): a novel serological biomarker for ovarian cancer.

Leung F, Soosaipillai A, Kulasingam V, Diamandis EP.

Clin Biochem. 2012 Dec;45(18):1543-6. doi: 10.1016/j.clinbiochem.2012.08.011. Epub 2012 Aug 17.

11.

Interlaboratory reproducibility of selective reaction monitoring assays using multiple upfront analyte enrichment strategies.

Prakash A, Rezai T, Krastins B, Sarracino D, Athanas M, Russo P, Zhang H, Tian Y, Li Y, Kulasingam V, Drabovich A, Smith CR, Batruch I, Oran PE, Fredolini C, Luchini A, Liotta L, Petricoin E, Diamandis EP, Chan DW, Nelson R, Lopez MF.

J Proteome Res. 2012 Aug 3;11(8):3986-95. doi: 10.1021/pr300014s. Epub 2012 Jul 3.

12.

Identification of five candidate lung cancer biomarkers by proteomics analysis of conditioned media of four lung cancer cell lines.

Planque C, Kulasingam V, Smith CR, Reckamp K, Goodglick L, Diamandis EP.

Mol Cell Proteomics. 2009 Dec;8(12):2746-58. doi: 10.1074/mcp.M900134-MCP200. Epub 2009 Sep 23.

13.

Activated leukocyte cell adhesion molecule: a novel biomarker for breast cancer.

Kulasingam V, Zheng Y, Soosaipillai A, Leon AE, Gion M, Diamandis EP.

Int J Cancer. 2009 Jul 1;125(1):9-14. doi: 10.1002/ijc.24292.

14.

Mining the ovarian cancer ascites proteome for potential ovarian cancer biomarkers.

Kuk C, Kulasingam V, Gunawardana CG, Smith CR, Batruch I, Diamandis EP.

Mol Cell Proteomics. 2009 Apr;8(4):661-9. doi: 10.1074/mcp.M800313-MCP200. Epub 2008 Dec 1.

Supplemental Content

Loading ...
Support Center